Science China Life Sciences, Journal Year: 2024, Volume and Issue: 67(6), P. 1311 - 1313
Published: March 4, 2024
Language: Английский
Nature Immunology, Journal Year: 2024, Volume and Issue: 25(2), P. 307 - 315
Published: Jan. 5, 2024
Language: Английский
Citations
22
Molecular Therapy, Journal Year: 2024, Volume and Issue: 32(6), P. 1779 - 1789
Published: April 24, 2024
Language: Английский
Citations
21
Cell Insight, Journal Year: 2024, Volume and Issue: 3(5), P. 100185 - 100185
Published: July 14, 2024
Monkeypox virus (MPXV) is a DNA belonging to the
Language: Английский
Citations
14
Deleted Journal, Journal Year: 2024, Volume and Issue: 6(7), P. 118 - 125
Published: Jan. 1, 2024
On July 23, 2022, the World Health Organization (WHO) declared monkeypox (mpox) outbreak a "Public Emergency of International Concern." Since outbreaks mpox in many countries around world have primarily resulted fatalities among immunocompromised individuals, such as untreated HIV/AIDS patients. eradication smallpox was by WHO 1980, global vaccination against has been gradually discontinued. China also stopped routine 1981. The protective effect vaccine decreased over time due to aging and declining immunity those who were vaccinated. For timely is an effective means protection mpox. However, safety concerns with limitations current vaccines, there no that safe, effective, low side effects applied clinical settings. This article provides comprehensive review development virus (MPXV) their application special populations, state research, considering etiology, transmission, prevention MPXV. Vaccination, method epidemic prevention, can provide long-term immune effectively reduce severity infection. licensed specific MPXV available globally, vaccines currently used for are mostly vaccines. These offer some degree activating cross-protection body.
Language: Английский
Citations
13
Cell Reports, Journal Year: 2024, Volume and Issue: 43(6), P. 114269 - 114269
Published: May 23, 2024
The 2022 mpox outbreak led the World Health Organization (WHO) to declare it a public health emergency of international concern (PHEIC). There is need develop more effective and safer virus (MPXV)-specific vaccines in response epidemic. mRNA vaccine promising platform protect against MPXV infection. In this study, we construct two bivalent vaccines, designated LBA (B6R-A29L) LAM (A35R-M1R), quadrivalent vaccine, LBAAM (B6R-A35R-A29L-M1R). immunogenicity protective efficacy these alone or combination were evaluated lethal mouse model. All candidates could elicit potential antigen-specific humoral cellular immune responses provide protection vaccinia (VACV) effect was superior that individual vaccine. Our study provides valuable insights for development efficient mpox.
Language: Английский
Citations
11
EBioMedicine, Journal Year: 2024, Volume and Issue: 109, P. 105392 - 105392
Published: Oct. 18, 2024
Language: Английский
Citations
9
Therapeutic Advances in Vaccines and Immunotherapy, Journal Year: 2025, Volume and Issue: 13
Published: Jan. 1, 2025
Given the surge in mpox outbreaks 2022 and advancements domestic international vaccine research, effectiveness of smallpox vaccines providing cross-protection against remains crucial. Having learned from COVID-19 pandemic, it is significant to continue evaluating existing ensure their safety efficacy. Developing new for widespread use its emerging strains also serves as a preventive strategy ongoing battle this dynamic infection. Here's an opportunity control human-to-human transmission, give short deadlines, avoid disparity. Public health systems must take decisive action prevent global spread mpox, particularly among vulnerable groups. This should include strengthening surveillance, improving access, ensuring equitable distribution, resource-poor settings, future outbreaks. review aims assess recent barriers development, emphasizing distribution settings.
Language: Английский
Citations
1
Chemical Engineering Journal, Journal Year: 2025, Volume and Issue: unknown, P. 160670 - 160670
Published: Feb. 1, 2025
Citations
1
Microorganisms, Journal Year: 2023, Volume and Issue: 11(11), P. 2713 - 2713
Published: Nov. 6, 2023
Monkeypox, a rare but significant zoonotic and orthopoxviral disease, has garnered increasing attention due to its potential for human-to-human transmission recent resurgence in multiple countries throughout Europe, North America, Oceania. The disease emerged as novel threat the global health systems that are still striving recover from major shocks of COVID-19 pandemic. unusual manifestation illness highlights substantial knowledge deficit necessitates immediate development public action strategy, considering epidemiological differences observed ongoing outbreak appearance cases non-endemic nations. This literature review aims synthesize existing on monkeypox, encompassing historical context, etiology, epidemiology, surveillance, prevention, transmission, clinical presentation, diagnosis, treatments, outbreak. Particular is given both advances gaps our understanding we point toward future directions research intervention efforts pertains vaccine distribution. Lastly, will also through sociopolitical lens relates decision-making strategies, especially lessons learned COVID-19.
Language: Английский
Citations
20
Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14
Published: Nov. 2, 2023
Tuberculosis (TB) remains a serious public health threat around the world. An effective vaccine is urgently required for cost-effective, long-term control of TB. However, only licensed Bacillus Calmette-Guerin (BCG) limited to prevent TB its highly variable efficacy. Substantial progress has been made in research and development (R&D) vaccines past decades, dozen candidates, including live attenuated mycobacterial vaccines, killed adjuvanted subunit viral vector messenger RNA (mRNA) were developed clinical trials date. Nevertheless, many challenges successful authorization use deployment an tuberculosis remain. Therefore, it still necessary urgent continue exploring new construction approaches. Virus-like particles (VLPs) present excellent prospects field because their helpful immunological features such as being safe templates without containing nucleic acid, repetitive surface geometry, conformational epitopes similar natural viruses, enhancing both innate adaptive immune responses. The marketization process VLP never stopped despite face several shortcomings complex slow high production cost, VLP-based against Human papillomavirus (HPV), Hepatitis B Virus (HBV) malaria, are successfully at market. In this review, we provide update on current regarding seek give overview candidates.
Language: Английский
Citations
19